{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Reference to Clinical Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Schedule of Activities to Appendix 2 for details on clinical lab tests."
      },
      {
        "id": "ref_2",
        "name": "Reference to Schedule of Activities from Study Assessments",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9 to Section 2 for the timing of study procedures."
      },
      {
        "id": "ref_3",
        "name": "Reference to Laboratory Tests Appendix from Study Assessments",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9 to Appendix 2 for a list of laboratory tests."
      },
      {
        "id": "ref_4",
        "name": "Reference to Blood Sampling Summary Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference from Section 9 to Appendix 5 for a summary of invasive samples."
      },
      {
        "id": "ref_5",
        "name": "Reference to Post Glucagon Administration Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.3",
        "sectionTitle": "Post Glucagon Administration",
        "description": "Reference from Section 9.1 to Section 9.2.3 for plasma glucose measurement details."
      },
      {
        "id": "ref_6",
        "name": "Reference to Edinburgh Hypoglycemia Scale Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.1.3 to Appendix 7 for the self-reported assessment tool."
      },
      {
        "id": "ref_7",
        "name": "Reference to Schedule of Activities from Efficacy Assessments",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.1.3 to Section 2 for timing of hypoglycemia symptom assessment."
      },
      {
        "id": "ref_8",
        "name": "Reference to Clarke Hypoglycemia Awareness Survey Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "description": "Reference from Section 9.1.3 to Appendix 8 for the self-report assessment tool."
      },
      {
        "id": "ref_9",
        "name": "Reference to Schedule of Activities from Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.2.1 to Section 2 for timing of PG and glucagon measurements."
      },
      {
        "id": "ref_10",
        "name": "Reference to Treatment Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference from Section 9.2.2 to Section 7 for details regarding treatments."
      },
      {
        "id": "ref_11",
        "name": "Reference to Nasal and Non-nasal Score Questionnaire Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.2.2.1 to Appendix 6 for a copy of the questionnaire."
      },
      {
        "id": "ref_12",
        "name": "Reference to Nasal and Non-nasal Score Questionnaire from AE Monitoring",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.3.1.2 to Appendix 6 for the questionnaire."
      },
      {
        "id": "ref_13",
        "name": "Reference to Edinburgh Hypoglycemia Scale from AE Monitoring",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.3.1.2 to Appendix 7 for the scale."
      },
      {
        "id": "ref_14",
        "name": "Reference to Laboratory Tests Appendix from Safety Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9.5.1 to Appendix 2 for details on laboratory tests."
      },
      {
        "id": "ref_15",
        "name": "Reference to Schedule of Activities from Safety Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.5.1 to Section 2 for timing of laboratory tests."
      },
      {
        "id": "ref_16",
        "name": "Reference to Schedule of Activities for Vital Signs",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.5.2 to Section 2 for timing of vital sign measurements."
      },
      {
        "id": "ref_17",
        "name": "Reference to Schedule of Activities for ECGs",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.5.3 to Section 2 for timing of ECG collection."
      },
      {
        "id": "ref_18",
        "name": "Reference to Hepatic Monitoring Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference from Section 9.5.5.2 to Appendix 4 for a list of liver tests."
      },
      {
        "id": "ref_19",
        "name": "Reference to Schedule of Activities for Pharmacokinetics",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.6 to Section 2 for timing of pharmacokinetic blood sample collection."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_3",
        "text": "Serum pregnancy test will be performed at screening. Urine pregnancy test will be performed at every admission period and follow-up visit if applicable.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_4",
        "text": "If a patient sneezes immediately after administration, document using the Nasal and Non-nasal Score Questionnaire (see Appendix 6 for a copy of the questionnaire).",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.2.2.1. Nasal LY900018 Administration",
        "pageNumber": 36
      },
      {
        "id": "annot_5",
        "text": "If an SAE occurs after signing informed consent, but prior to receiving investigational product, AND is considered reasonably possibly related to a study procedure then it MUST be reported.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1. Serious Adverse Events",
        "pageNumber": 39
      },
      {
        "id": "annot_6",
        "text": "Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1. Serious Adverse Events",
        "pageNumber": 39
      },
      {
        "id": "annot_7",
        "text": "For the purposes of this study, an overdose of LY900018 or IMG is considered any dose that is higher than the assigned dose.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4. Treatment of Overdose",
        "pageNumber": 40
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8R-JE-IGBJ(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Protocol Amendment (a) approved on 05-Dec-2017. Base protocol approved on 26-Oct-2017.",
        "amendmentNumber": "Amendment (a)"
      }
    ],
    "summary": {
      "referenceCount": 19,
      "annotationCount": 7,
      "versionCount": 1
    }
  }
}